Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The global burden of pulmonary hypertension in sickle cell disease: a systematic review and meta-analysis
source: Annals of Hematology
year: 2016
authors: Musa BM, Galadanci NA, Coker M, Bussell S, Aliyu MH
summary/abstract:Elevated tricuspid regurgitant jet velocity (TRJV) is a surrogate measure of pulmonary hypertension (PH) in persons with sickle cell disease (SCD). We sought to estimate the burden of PH in people living with sickle cell disease based on TRJV. From 2000 to 2015, we searched electronic databases for eligible publications and included 29 studies (n = 5358 persons). We used random effects modeling to determine the pooled estimate of elevated TRJV. The overall pooled prevalence of elevated TRJV was 23.5 %(95 % CI 19.5-27.4) in persons with SCD. The pooled prevalence of elevated TRJV in children and adults with SCD was 20.7 % (95 % CI 15.7–25.6) and 24.4 % (95 % CI 18.4-30.4), respectively. TRJV is prevalent among adults and children with SCD. Our finding support international recommendations that call for screening for PH in SCD patients.
organization: Bayero University/Aminu Kano Teaching Hospital; University of Maryland; Vanderbilt University School of Medicine, Nashville; Meharry Medical College, NashvilleDOI: 10.1007/s00277-016-2693-z
read more full text
+myBinderRelated Content
-
Pathophysiology and treatment of pulmonary hypertension in sickle cell diseasePulmonary hypertension affects ∼10% of...
-
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysisThe cell adhesion molecule P-selectin pl...
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
Sickle Cell Disease and Cold Weather: Dos and Don’tsIn the United States today, one of every...
-
CTX001 Continues to Show Promise in Severe SCDA single dose of CTX001, an experimental...
-
SUSTAIN Clinical Trial Results Show Crizanlizumab Reduced Sickle Cell–Related Pain CrisesResults from the Phase 2 SUSTAIN clinica...
-
Study challenges view that sickle cell trait increases mortality riskSurprising findings from a study of heal...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.